Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.
Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.
Urology. 2023 Nov;181:98-104. doi: 10.1016/j.urology.2023.07.020. Epub 2023 Jul 29.
To compare the perioperative outcomes of transvesical single-port robotic simple prostatectomy (SP-RASP) and holmium laser enucleation of the prostate (HoLEP).
A retrospective review was performed of patients undergoing SP-RASP and HoLEP from 2019 to 2022 with preoperative prostatic volume (PPV) >80 cm. Percent of prostate adenoma removed (%PAR) was estimated by specimen weight normalized by PPV. Univariate analysis was performed using chi-square, Fisher exact, and Wilcoxon rank-sum tests. A subgroup analysis with 1:1 matching for PPV was also performed.
A total of 50 SP-RASP and 90 HoLEP cases were analyzed. The median (interquartile range) PPV was 169 (128-244)cm for SP-RASP and 129 (100-150)cm for HoLEP, (P < .01). The median (interquartile range) %PAR was 57(44-68) for SP-RASP vs 51(42-62) for HoLEP (P = .10). Overall, 11(12%) HoLEP and 5(10%) SP-RASP patients experienced complications (P = .51). Same-day discharge occurred in 24(48%) SP-RASP vs 7(8%) HoLEP patients (P < .01). Median foley catheter duration was longer in SP-RASP (6 vs 1 day, P < .01) and trial of void was successful at first attempt in >94% (P = .68). Transient de novo incontinence was reported in 24(28%) HoLEP vs 2(5%) SP-RASP (P < .01). No differences in voiding parameters were observed at latest follow up. Subgroup postmatched analysis revealed analogous findings.
SP-RASP and HoLEP have similar favorable perioperative outcomes for management of large prostatic adenomas. SP-RASP may be considered in patients unwilling to accept the risk of transient incontinence and in those with unfavorable urethral access, large bladder stone burden, or diverticula.
比较经膀胱单孔机器人前列腺切除术(SP-RASP)和钬激光前列腺剜除术(HoLEP)的围手术期结果。
回顾性分析 2019 年至 2022 年期间接受 SP-RASP 和 HoLEP 治疗且术前前列腺体积(PPV)>80cm 的患者。通过将标本重量除以 PPV 来估计前列腺腺瘤切除百分比(%PAR)。采用卡方检验、Fisher 确切检验和 Wilcoxon 秩和检验进行单变量分析。还对 PPV 进行了 1:1 匹配的亚组分析。
共分析了 50 例 SP-RASP 和 90 例 HoLEP 病例。SP-RASP 的中位(四分位间距)PPV 为 169(128-244)cm,HoLEP 为 129(100-150)cm(P<0.01)。SP-RASP 的中位(四分位间距)%PAR 为 57(44-68),HoLEP 为 51(42-62)(P=0.10)。总体而言,11(12%)例 HoLEP 和 5(10%)例 SP-RASP 患者发生并发症(P=0.51)。24(48%)例 SP-RASP 患者和 7(8%)例 HoLEP 患者当天出院(P<0.01)。SP-RASP 的导尿管留置时间中位数为 6 天,而 HoLEP 为 1 天(P<0.01),首次尝试排尿试验成功率>94%(P=0.68)。24(28%)例 HoLEP 患者和 2(5%)例 SP-RASP 患者报告出现短暂性新发尿失禁(P<0.01)。在最新随访时,排尿参数无差异。亚组后匹配分析显示出类似的结果。
SP-RASP 和 HoLEP 治疗大体积前列腺腺瘤具有相似的围手术期良好效果。对于不愿意接受短暂性尿失禁风险的患者,以及对于尿道入路不佳、膀胱结石负荷大或憩室的患者,可考虑采用 SP-RASP。